Study backs rapid test for "super bugs":
This article was originally published in Clinica
Executive Summary
Canadian firm ID Biomedical will file in February for FDA-clearance to market its rapid test for methicillin-resistant Staphylococcus aureus (MRSA) after receiving promising preliminary results in US clinical trials. The test for the potentially fatal so-called "superbugs", which are becoming increasingly prevalent in hospitals, was shown to have an accuracy of 100% in an analysis of 308 samples. The Velogene Rapid MRSA test, which is based on the Vancouver, British Columbia company's Cycling Probe Technology, detects the mecA gene responsible for antibiotic resistance.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.